Author

Carl G. Chakmakjian

Observed names: C. Chakmakjian, Carl Chakmakjian

Institution: Texas Oncology

Observed institutions: Texas Oncology, Baylor Scott & White Medical Center - Temple, Scott & White Memorial Hospital, Texas A&M University

OpenAlex ID: A5032548393

Tumor Lysis Syndrome in Solid Tumors

2005 · Frank E. Mott, Alex Esana, et al. · Supportive Cancer Therapy · 49

Von Recklinghausen's Disease and Breast Cancer

2005 · Juan G. Posada, Carl G. Chakmakjian · New England Journal of Medicine · 15

An open-label phase 3b/4 safety trial of flat-dose nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)

2017 · L. Paz-Ares, B. Lash, et al. · Annals of Oncology · 1

Rucaparib vs docetaxel (DTX) or second-generation androgen receptor pathway inhibitor (ARPI) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations based on Eastern Cooperative Oncology Group performance status (ECOG PS) in TRITON3.

2026 · M. Neil Reaume, Karim Fizazi, et al. · Journal of Clinical Oncology

Abstract CT070: A open-label phase 3b/4 safety trial of flat-dose nivolumab in combination with ipilimumab in patients with advanced non-small cell lung cancer (NSCLC)

2017 · Rathi N. Pillai, Bradley Lash, et al. · Cancer Research

RBC Histogram Predictive of HE.

2005 · Carl Chakmakjian, Ed Rappaport · Blood

Works count: 6

Citation count: 65

H-index: 2

I10-index: 2